GP6 and rheumatoid arthritis: To date, the SCHOOL peptides that target TREM-1, glycoprotein receptor VI (GPVI), and TCR were demonstrated both in vitro and in vivo to represent promising therapeutic approaches to the treatment of a variety of diseases with unmet clinical need including sepsis, lung cancer, rheumatoid arthritis, dermatoses, and others33,34,52,58,60.